Study of Remdesivir Treatment for Upper Respiratory Tract RSV Infection in Patients Receiving Cellular or Bispecific Antibody Therapies

What this Trial Is About

Researchers are evaluating how well remdesivir works for treating respiratory syncytial virus RSV infections in the upper respiratory tract of patients who have weakened immune systems due to cellular or bispecific antibody therapies. These therapies suppress the immune system, making infections like RSV more common and potentially severe, leading to pneumonia or death. This phase II trial aims to assess remdesivir, an antiviral medication that stops viruses from spreading in the body, in this vulnerable population. Participants receive remdesivir through an intravenous IV infusion lasting 30 to 120 minutes daily from day 1 to day 5, with the option to extend treatment up to day 10 if the investigator deems it necessary and if there is no disease progression or unacceptable side effects. Throughout the study, patients undergo nasal swabs and blood sample collection. After completing treatment, participants are followed up on days 14 and 29 to monitor their health status. During the study, participants will be assessed for the need for supplemental oxygen, hospitalizations, adverse events, and changes in viral load from nasal swabs. Researchers also evaluate respiratory symptoms using the Respiratory Infection Intensity and Impact Questionnaire RiiQ. Safety and tolerability are monitored throughout the trial, with follow-up visits on day 14 and day 29. The total participation time includes treatment days and follow-up assessments to understand remdesivirs impact on RSV infection in the immune-compromised population.

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals